

**DETAILS OF WORKS / CONSULTANCY / PURCHASE CONTRACTS AWARDED ON NOMINATION BASIS**

**4TH QUARTER OF 2020 - 21 (JAN 2021 - MAR 2021)**

**DETAILS OF PURCHASE CONTRACTS**

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
SR. NO	Name of Work/Description of Item	Tender/Quotation No. & Date	Name of Agency	P.O. No. & DATE	Purchase Order Value (Rs. in Lakhs)	Contract Period	Reasons for Nomination	Approving Authority	UNIT
1	Cap. Radiogardase-CS, Inj. Ca-DTPA & Inj. Zinc-DTPA	CMM/OPS/00-10-9-3276 dated 30-10-2019	M/s. HEYL	CMM/OPS/00-10-9-3276/PO/45030 dated 01-02-2021	15.93	01-03-2021	The proposed medicine are antidotes / decorporating agents for use in the event of an accidental radioactive contamination and are in the nature of essential stock to be maintained as per regulatory requirements of AERB. Though the medicines are 'proprietary' in nature, in view of specific provision in the HQI 3009 (R-1) Clause 8 (a) the procurement is treated to be on "NOMINATION" basis for the purpose of DFP as these medicines are not listed in approved pharmacopeia.	ED (HR)	HQ